Knowledge, attitudes, and practices towards the use of GLP-1 receptor agonists for weight loss among the general population in Jordan; A cross-sectional study

Знания, отношение и практика применения агонистов рецепторов ГПП-1 для снижения массы тела среди населения Иордании: одномоментное исследование
Muna M. Barakat, Rana Abutaima, Hana M. Sawan, Shatha M. Al Omari, Nizar Mahmoud Mhaidat
2024-12-05

GLP-1 receptor agonistsJordanian populationantidiabetic medicationscross-sectional studyweight management
INTRODUCTION: Obesity has emerged as a global pandemic, with its prevalence notably increasing during the COVID-19 lockdown of 2019. In response, many individuals have turned to pharmacological interventions, including antidiabetic medications, as means of achieving weight loss with minimal effort. This study aims to assess the knowledge, attitudes, and practices of the Jordanian population regarding the use of antidiabetic agents, specifically glucagon-like peptide-1 receptor agonists and biguanides, for weight management. METHOD: A self-administered validated online questionnaire was developed and disseminated to public utilizing a cross-sectional design. Data were extracted to examine descriptive statistics. Linear regression was performed to evaluate associations with knowledge and attitude. A p-value ≤0.05 was chosen to indicate statistical significance. RESULTS: Total of 389 responses were analyzed, 65.6% females, 54.2% married, 78.1% living in the center of Jordan, 35.5% overweight and 26.5% have >1000 Jordanian Dinars monthly income. Fifty seven percent of the study participants think that antidiabetics could be used for weight loss. 47.27%, 44.55%, 68.18% recognized glucagon-like peptide-1receptor agonists; (Ozempic®), (Saxenda®), (Mounjaro®) as well as (Glucophage®) use for weight loss, respectively and 12.3% of participants used medications to lose weight. Neutral attitude was observed. Gender and body mass index were significantly affecting the participants knowledge (p<0.001, p = 0.002, respectively). CONCLUSION: Use of (Ozempic®), (Saxenda®) and other antidiabetics to lose weight become a common practice. The results of this study suggests supervising prescription and dispensing to avoid misuse, especially, in people who are contraindicated to use them.
1
Among 389 Jordanian respondents, 57% believed antidiabetic medications could be used for weight loss, while 12.3% reported using medications for this purpose.
2
Gender and body mass index were significantly associated with knowledge about these medications (p<0.001 and p=0.002, respectively).
3
Participants generally demonstrated a neutral attitude toward using GLP-1 receptor agonists and biguanides for weight management.
4
Recognition of weight-loss use varied across medications: 47.27% for Ozempic, 44.55% for Saxenda, 68.18% for Mounjaro, and the reported proportion for Glucophage was included in the study results.
5
The findings indicate common use of antidiabetic agents for weight loss and support supervised prescribing and dispensing to reduce misuse, particularly among contraindicated individuals.

Jordanian general population using antidiabetic agents, particularly GLP-1 receptor agonists and biguanides, for weight loss

Knowledge, attitudes, and practices regarding the use of GLP-1 receptor agonists and biguanides for weight management

Publication Details
Publication Date
2024-12-05
Journal
Publisher
ISSN
Cited by
14
Access Type
Author Information
Authors
Muna M. Barakat
Rana Abutaima
Hana M. Sawan
Shatha M. Al Omari
Nizar Mahmoud Mhaidat
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%